Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK.GSK on Thursday filed a lawsuit in Delaware federal court accusing Pfizer and BioNTech of infringing five patents related to the mRNA technology behind the partners’ COVID shot Comirnaty.

在Moderna提起的新型冠状病毒肺炎疫苗专利诉讼中胜诉后不久，辉瑞及其德国合作伙伴BioNTech正被GSK拖入另一轮mRNA诉讼。葛兰素史克（GSK）周四在特拉华州联邦法院提起诉讼，指控辉瑞（Pfizer）和生物科技（BioNTech）侵犯了与合作伙伴新型冠状病毒（COVID shot Comirnaty）背后的mRNA技术相关的五项专利。

The relevant mRNA research was conducted “more than a decade” before the COVID-19 pandemic and was picked up by GSK in 2015 when the company acquired a “substantial portion” of Novartis’ global vaccine business, according to the lawsuit.GSK claims Pfizer and BioNTech subsequently “reaped billions of dollars in revenue from infringing GSK’s Patents-in-Suit and continue to benefit, without ever obtaining a license.”Now, the British drugmaker is seeking a “reasonable royalty” from Pfizer and BioNTech, as well as a compulsory ongoing licensing fee for the partners’ alleged use of GSK’s patented mRNA technology.RelatedWhile Moderna moves off COVID, Spikevax posts market-share gains on Pfizer rivalA GSK spokesperson confirmed over email that the company filed suit and said it’s “committed to taking appropriate action where necessary to protect the company’s intellectual property.” She described the GSK patents in question as “foundational” to Pfizer and BioNTech’s mRNA vaccines.GSK would be “willing to license these patents on commercially reasonable grounds” to make sure patients continue to enjoy access to Pfizer and BioNTech’s shots, the spokesperson added.Pfizer, for its part, remains “confident” in its intellectual property (IP) position and intends to “vigorously defend against [GSK’s] claims,” a company spokesperson said in a statement.The latest lawsuit in Delaware marks the opening of a new front i.

诉讼称，相关的mRNA研究是在新型冠状病毒肺炎大流行之前“十多年”进行的，2015年葛兰素史克收购了诺华全球疫苗业务的“大部分”后，该研究被葛兰素史克收购。葛兰素史克（GSK）声称，辉瑞（Pfizer）和生物科技（BioNTech）随后“从侵犯葛兰素史克（GSK）专利的诉讼中获得了数十亿美元的收入，并继续受益，但从未获得许可证”。现在，这家英国制药商正在向辉瑞（Pfizer）和生物科技（BioNTech）寻求“合理的特许权使用费”，以及对合作伙伴涉嫌使用葛兰素史克（GSK）mRNA专利技术的强制持续许可费。与此相关的是，虽然Moderna不再使用新型冠状病毒，但Spikevax在辉瑞rivalA上发布了市场份额增加的消息。葛兰素史克发言人在电子邮件中证实，该公司已提起诉讼，并表示“承诺在必要时采取适当行动保护公司的知识产权”。她将有关的葛兰素史克专利描述为辉瑞和BioNTech mRNA疫苗的“基础”。这位发言人补充说，葛兰素史克将“愿意以商业上合理的理由许可这些专利”，以确保患者继续享受辉瑞和BioNTech的注射。辉瑞公司发言人在一份声明中表示，辉瑞公司对其知识产权（IP）立场仍“充满信心”，并打算“对葛兰素史克（GSK）的索赔进行有力辩护”。特拉华州的最新诉讼标志着一个新战线的开启。